Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVX201 in Relapsed/Refractory AML and MDS
NCT04901416Phase 1Completed
- Sponsor
- Coeptis Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic natural killer cells DVX201 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN), sponsored by Coeptis Pharmaceuticals. Primary endpoint: Incidence of Dose Limiting Toxicities. Started Dec 2021; status: completed.
02
Drugs
allogeneic natural killer cells DVX201
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Beyond the preview
Go deeper on NCT04901416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901416.